



Devin Geng | Associate

耿德文 | 律师

devin.geng@pillsburylaw.com

Shanghai
Suite 1115, 11th Floor, Bund Center
222 Yan An Road East
Huangpu District, Shanghai 200002
China
Ph. +86.21.6137.7923
Fax +86.21.6137.7900



- Corporate 公司业务
- China 中国事务
- Capital Markets 证券和资本市场
- Mergers & Acquisitions 并购
- Foreign Corrupt Practices Act & Global Anti-Corruption 反腐败和反海外贿赂法

Devin Geng is an associate in the firm's corporate practice. Devin's primary practice includes U.S. and Hong Kong capital market transactions, M&A and FCPA-related compliance matters.

耿德文律师是我所公司业务的律师。他的主要业务重心包括美国、香港资本市场、兼并收购与投资，也包括美国反海外腐败法以及其它与合规相关的法律。

Devin is also rapidly becoming a go-to lawyer in the biotechnology industry in China. His involvement in the industry began in 2018, when he was counsel for one of the first companies to be successfully listed under the HKEx's Chapter 18A for pre-revenue biotechnology companies. Since then, Devin has represented numerous biotechnology companies for PE investments, capital market transactions and other transactions. He represented SinoMab, GenScript, ProBio and Mega Genomics, and other prominent biotechnology companies.

耿律师迅速成为生物技术行业的专业律师。他参与该行业的工作始于 2018 年，当时他担任一家公司的法律顾问为此公司在港交所 18A 适用于尚未盈利的生物技术公司成功上市。耿律师代表众多生物技术公司就私募股权投资、资本市场等交易提供法律服务。他曾代表 SinoMab、GenScript、ProBio 和 Mega Genomics 以及其他知名生物技术公司。

Representative Experience

代表性经验

- Advised SinoMab BioScience Limited in its global offering and IPO on the main board of the Hong Kong Stock Exchange. SinoMab BioScience is one of the earliest companies listed under Chapter 18A of the Hong Kong listing rules for pre-revenue biotechnology companies.

为 SinoMab BioScience Limited 在香港证券交易所主板的全球发售和首次公开募股事提供法律服务。SinoMab BioScience 是最早根据香港上市规则第 18A 章（针对尚未盈利的生物技术公司）上市的公司之一。



- Advised MultiMetaVerse in its \$300 million de-SPAC transaction and subsequent listing on the NASDAQ. MultiMetaVerse is an animation, entertainment and mobile game company. The de-SPAC transaction took place at the height of domestic regulations on the gaming industry, and the transaction team was able to overcome significant hurdles to successfully close the transaction.

为 MultiMetaVerse 完成其 3 亿美元的 de-SPAC 交易以及后续的纳斯达克上市提供法律服务。MultiMetaVerse 是一家动画、娱乐和游戏公司。此交易在国内对游戏行业监管最严格的时期进行，交易团队克服了重重困难，成功完成了上市工作。

- Advised GenScript Biotech, a U.S.-based biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology in Probio Technology's series financing since its establishment with prominent institutional investors and state funds.

为 GenScript Biotech（一家专注于基因合成技术的美国生物技术公司）及其间接全资子公司 Probio Technology 为 Probio Technology 自成立以来与知名机构投资者和国有基金的一系列融资中提供顾问服务。

- **Corporate**

公司

- Advised Probio Technology in its Series C financing with investments from Legend Capital, Highlight Capital, Hillhouse Capital (Probio's Series A investor) and other prominent institutional investors. Probio Technology raised approximately \$224 million from the Series C investors.

代表 Probio Technology，完成与君联资本、弘晖基金、高瓴资本（蓬勃生物的 A 轮融资投资者）以及其他知名机构投资者的 C 轮融资交易。C 轮投资人认购 Probio Technology 股权的总价值约 2.24 亿美元。

- Advised MultiMetaVerse in its \$300 million de-SPAC transaction and subsequent listing on the NASDAQ. MultiMetaVerse is an animation and entertainment company devoted to establishing an open community for its global users by providing high-quality entertainment experiences.

代表 MultiMetaVerse 完成其 3 亿美元的 de-SPAC 交易以及后续的纳斯达克上市。MultiMetaVerse 是一家动画和娱乐公司，致力于通过提供高质量的娱乐体验为其全球用户建立一个开放的社区。

- Advised Mega Genomics Limited in its HK\$215 million global offering and IPO on the main board of the Hong Kong Stock Exchange. Mega Genomics is the largest consumer genetic testing platform in China.

代表 Mega Genomics 完成其 2.15 亿港币的全球发行以及在香港联合交易所主板的首次公开发行。美因基因是中国最大的消费者基因检测平台公司。

- Advised Probio Technology in its Series B financing transaction from Zhenjiang High-tech Venture Capital (HK) Limited, who subscribed minority equity interest in Probio Technology for \$37.3 million. The transaction is executed concurrently with a real estate acquisition by Probio Technology from Zhenjiang High-tech Venture Capital.

代表 Probio Technology，完成与镇江高新创业投资（香港）有限公司的 B 轮融资交易。镇江高新创业投资（香港）有限公司以 3,730 万美元认购 Probio Technology 的少数股权。该交易与 Probio Technology 收购镇江高新创业投资（香港）有限公司名下地产同时完成。

- Advised De Well, an international logistics company, on the subscription of its equity interest by an investing vehicle of Cainiao, a global logistics service provider under Alibaba Group.

代表国际物流公司德威集团获菜鸟网络旗下的投资平台认购其股权。菜鸟网络是阿里巴巴集团旗下一家全球物流服务提供商。

- Advised GenScript Biotech, a U.S.-based biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology, in Probio Technology's Series A financing transaction from Hillhouse Capital, who subscribed minority equity interest in Probio Technology for \$150 million, with a \$125 million warrant to purchase additional shares.

代表 GenScript Biotech，一家专注于基因合成技术的美国生物科技公司，及其间接全资附属公司 Probio Technology，完成与私募股权投资基金高瓴资本的 A 轮融资交易。高瓴资本以 1.5 亿美元认购 Probio Technology 的少数股权，并获得总价 1.25 亿美元的额外认股权证。

- Advised SinoMab BioScience Limited in its global offering and IPO on the main board of the Hong Kong Stock Exchange. SinoMab BioScience is listed on the HKSE under Chapter 18A of the Hong Kong listing rules.

代表 Sinomab 完成其全球发售和在香港联合交易所主板的首次公开发行。中国抗体制药有限公司是一家根据港交所上市规则 18A 上市的医药公司。

- Advised Fosun Tourism Group in its \$428 million global offering and IPO on the Hong Kong Stock Exchange.

代表复星旅游文化集团完成其 4.28 亿美元的全球发售和在香港联合交易所主板的首次公开发行。此交易被《金融时报亚太创新律师报告》评为“2019 年最创新交易”之一。

- Advised Mei Nian Investment and Meinian Onehealth as the issuer and parent guarantor, respectively, for Mei Nian Investment's issuance of \$200 million guaranteed senior notes due in 2021. Meinian Onehealth is one of the largest private health checkup service providers in China.

代表 Mei Nian Investment 及美年大健康分别作为发行人及母公司担保人发行于 2021 年到期的 2 亿美元担保优先票据。美年大健康是中国最大的私营专业健康体检和医疗服务供应商之一。

- Advised Liaoning Port Co., Ltd. for its HKEX disclosures regarding its merger by absorption with Yingkou Port Liability Co., Ltd.



代表辽宁港口股份有限公司为其与收购营口港务股份有限公司相关事务在香港交易所进行相关的披露。

- Advised a Chinese asset management company on its proposed U.S. initial public offering.

代表一家大型资产管理公司完成其拟在美国上市。

- **Litigation/Dispute Resolution/Compliance**

诉讼/ 争议解决/ 合规

- Advised a large PRC investment fund in arbitration at the HKIAC for an acquisition and contractual dispute with the client receiving compensation and damages from arbitration.

代表一家大型基金为其在收购中产生的合同纠纷在香港仲裁中心进行仲裁，并成功为客户获得赔偿。

- Advised a large Chinese state-owned enterprise on a contractual and intellectual property rights dispute against an American company, and successfully assisted the client in receiving compensation.

代表一家大型中国国有企业就其与一家跨国公司的合同及知识产权纠纷提供法律意见，并成功为客户获得赔偿。

- Advised multiple global pharmaceutical companies, medical device companies and technology companies in conducting a series of compliance investigations and periodic compliance reviews for their business operations in China. Participated in subsequent negotiations with government agencies regarding the investigation and provided remediation recommendations regarding the client companies' compliance policies.

代表多家国际医药公司、医疗器械公司及科技公司对其在中国大陆的业务进行一系列的合规调查，季度、年度合规审查，提供合规政策的改进意见，并参与了合规调查后与政府机构相关的汇报及沟通。

Professional Highlights

职业荣誉

- Member of the Shanghai Bar Association Specially-Invited Committee

上海律师协会特邀委员会会员

- Guest Lecturer at Fudan Law School (2020 - Present)



复旦大学法学院客座讲师 (2020-Present)

Education

教育

J.D., Emory University School of Law, 2014

埃默里大学法学院博士学位 (2014)

B.A., University of Michigan, 2009

密西根大学文学士学位 (2009)

Admissions

律师资格

New York

纽约州

Languages

语言

Chinese (Mandarin)

中文 (普通话) English

英语